AHAnna Heidbreder

Anna Heidbreder

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Heidbreder has a total of 303 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Shared Pathogenic Pathways Between REM Sleep Behavior Disorder and Neurodegenerative and Psychiatric Disorders

    by Zhao Zhang, Emma N. Somerville, Zih-Hua Fang, Lang Liu, Farnaz Asayesh, Jamil Ahmad, Saeid Amiri, Meron Teferra, Pauline Dodet, Isabelle Arnulf, et al.

    Isolated/idiopathic rapid-eye-movement (REM)-Sleep Behavior Disorder (iRBD) is characterized by dream enactment behaviors associated with loss of REM atonia. iRBD is in most cases a prodromal synucleinopathy, and emerging evidence suggests associations between RBD and other neurological and psychiatric conditions. In this study, we performed pathway-based polygenic risk score (PRS) and rare variant burden analyses to examine these potential associations. Pathway-specific PRS were constructed from genome-wide association study summary statistics of five neurodegenerative and seven psychiatric traits across 10 biologically relevant pathway categories, including a total of 279 pathways, in 1,573 iRBD cases and 16,022 controls from the International RBD Study Group and UK Biobank. Rare variant burden tests were performed in 1,264 iRBD cases and 2,581 controls. We identified multiple potential pathways indicating shared polygenic risk between RBD and both neurodegenerative and psychiatric disorders. Lewy body diseases and post-traumatic stress disorder had the most shared polygenic risk pathways in neurological and psychiatric disorders, respectively. Two pathways, the serotonin transport pathway and the chaperone-mediated autophagy pathway, showed the strongest association with iRBD, and gene-based rare variants analyses revealed five genes associated with iRBD: GBA1 , PLEKHM1 , LRP2 , P2RX1 , and HAP1. Subsequent analysis of these genes in Parkinson’s disease and dementia with Lewy bodies replicated several associations. Together, these findings provide novel insights into the shared genetic architecture underlying iRBD, neurodegenerative disorders, and psychiatric traits, with implications for early identification and mechanistic understanding.


  • Open Access

    Genome-wide association study of REM-sleep behaviour disorder identifies new risk loci

    by Emma N. Somerville, Lang Liu, Lynne Krohn, Farnaz Asayesh, Jamil Ahmad, Dan Spiegelman, Meron Teferra, Manuela Tan, Sheena Waters, Cristina Simonet, et al.

    Rapid-eye-movement (REM)-sleep behaviour disorder (RBD) can be a prodromal stage of α-synucleinopathies, including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), and provides a unique opportunity to study and understand early neurodegeneration. Previous research on RBD has identified common risk loci in several PD and DLB genes, but the full extent of its genetic architecture and disease-specific associations remain unknown. In the present study, we aimed to identify novel loci associated with RBD by conducting an updated European RBD genome-wide association study (GWAS). We performed a meta-analysis using a previous RBD GWAS and newly genotyped RBD patients and controls, resulting in a total of 3,564 RBD cases and 140,393 controls analyzed. We further assessed the functional impact of new associations using fine-mapping and colocalization analyses with adult brain expression quantitative trait loci (eQTLs). To confirm if novel RBD loci are implicated in additional synucleinopathy phenotypes, we examined common variant associations in GWASs of PD risk, DLB risk, PD with RBD risk, PD age at onset, and various measures of progression. Additionally, rare variants were analyzed with the optimal sequence kernel association test (SKAT-O) in PD and DLB whole genome sequencing cohorts. Lastly, we analyzed known PD- and DLB-risk loci for associations with RBD. We identified RCOR1 as a novel risk locus for RBD, with fine-mapping suggesting the association to be driven by a variant in intron 2. Colocalization revealed no evidence for shared genetic signals with brain eQTLs, although this may reflect a lack of statistical power to detect an association. Common and rare variants in the RCOR1 locus were not associated with PD, DLB, and additional α-synucleinopathy phenotypes. We observed several PD and DLB risk loci to be associated with RBD, including MAPT , STK39 , and SIPA1L2 . The MAPT associated variant tags the protective H2 haplotype, consistent with previous findings in PD. Several SNCA variants previously associated with PD or DLB were also associated with RBD, but with differing directions of effect, highlighting the complex genetic landscape underlying α-synucleinopathy subtypes. This study identifies new RBD loci and strengthens our understanding of the genetic modifiers underlying RBD. Further replication and functional studies will be required to validate our findings and explore their biological implications.

  • Open Access

    Sleep architecture and rapid eye movement sleep without atonia in post-COVID-19 insomnia

    by Abubaker Ibrahim, Matteo Cesari, Qi Tang, Merve Aktan Süzgün, Elisabeth Brandauer, Evi Holzknecht, Alexander Wachter, Victoria Anselmi, Anna Heidbreder, Ambra Stefani, et al.

    Study Objectives: Insomnia associated with COVID-19 infection is a common complaint in long-COVID. Studies to date have predominantly examined post-COVID-19 sleep disturbances with questionnaires. We aimed to investigate whether there are distinctive polysomnographic findings in post-COVID-19 insomnia compared to non-COVID-related chronic insomnia. Methods: We included 150 patients with chronic insomnia, stratified into three groups: post-COVID-19 insomnia (N = 50), chronic insomnia during the pandemic without a history of COVID-19 infection (N = 50), and pre-pandemic chronic insomnia (N = 50). All patients underwent one-night video-polysomnography (v-PSG). The sleep architecture, respiratory variables, and rapid eye movement (REM) sleep without atonia (RWA) were compared across the groups. Results: Classical polysomnographic variables showed no significant differences across groups with regard to total sleep time, sleep efficiency, sleep stage percentages, and the apnea–hypopnea index. Post-COVID-19 insomnia patients had significantly increased RWA at both the chin and the flexor digitorum superficialis (p=.020 for both), and higher nocturnal heart rates (p=.046). Sleep-bout analysis indicated shorter sustained N3-sleep periods (p=.001) and longer onset to stable REM sleep (p=.016) in the post-COVID-19 insomnia group. Although sleep transitions did not withstand multiple comparison corrections, they revealed a trend toward decreased N3-sleep continuity and increased probabilities of transitioning to lighter stages (N3 → N3: unadjusted-p=.012; REM → N1: unadjusted-p=.027) in the post-COVID-19 insomnia. Conclusions: Classical PSG profile of post-COVID-19 insomnia does not differ from non-COVID-related chronic insomnia. However, subtle differences in RWA and sleep integrity suggest that post-COVID-19 insomnia is driven not merely by pandemic-related stress factors but by additional physiological alterations linked to viral central nervous system involvement. Statement of Significance Insomnia is a major symptom in long-COVID, yet objective studies examining its electrophysiological underpinnings are scarce. We present the largest video-polysomnographic investigation comparing post-COVID-19 insomnia with chronic insomnia unrelated to COVID-19. While classical sleep architecture metrics did not significantly differ between post-COVID-19 insomnia and matched pre-pandemic and pandemic-era non-COVID-insomnia patients, our findings reveal subtle but important distinctions. Patients with post-COVID-19 insomnia exhibited significantly increased REM RWA, alongside trends toward altered sleep continuity, including shorter N3 sleep bouts, longer onset to stable REM sleep, and higher nocturnal heart rates. These findings suggest specific central nervous system alterations post-infection that go beyond stress-related pandemic effects and are likely linked to viral central nervous system effects. This highlights the unique neurobiological impact of COVID-19 on sleep regulation, meriting further investigation, even as established insomnia treatments remain applicable.


  • Motorik

    by Anna Heidbreder, Geert Mayer

  • Verwirrtes Erwachen

    by Anna Heidbreder

  • Parasomnien

    by Anna Heidbreder

  • Open Access

    Unsupervised Clustering in Neurocritical Care: A Systematic Review

    by Jeanette Tas, Verena Rass, Bogdan-Andrei Ianosi, Anna Heidbreder, Melanie Bergmann, Raimund Helbok

    Managing patients with acute brain injury in the neurocritical care (NCC) unit has become increasingly complex because of technological advances and increasing information derived from multiple data sources. Diverse data streams necessitate innovative approaches for clinicians to understand interactions between recorded variables. Unsupervised clustering integrates different data streams and could be supportive. Here, we provide a systematic review on the use of unsupervised clustering using NCC data. The primary objective was to provide an overview of clustering applications in NCC studies. As a secondary objective, we discuss considerations for future NCC studies. Databases (Medline, Scopus, Web of Science) were searched for unsupervised clustering in acute brain injury studies including traumatic brain injury (TBI), subarachnoid hemorrhage, intracerebral hemorrhage, acute ischemic stroke, and hypoxic-ischemic brain injury published until March 13th 2024. We performed the systematic review in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. We identified 18 studies that used unsupervised clustering in NCC. Predominantly, studies focused on patients with TBI (12 of 18 studies). Multiple research questions used a variety of resource data, including demographics, clinical- and monitoring data, of which intracranial pressure was most often included (8 of 18 studies). Studies also covered various clustering methods, both traditional methods (e.g., k-means) and advanced methods, which are able to retain the temporal aspect. Finally, unsupervised clustering identified novel phenotypes for clinical outcomes in 9 of 12 studies. Unsupervised clustering can be used to phenotype NCC patients, especially patients with TBI, in diverse disease stages and identify clusters that may be used for prognostication. Despite the need for validation studies, this methodology could help to improve outcome prediction models, diagnostics, and understanding of pathophysiology. Registration number: PROSPERO: CRD4202347097676.


  • Open Access

    Epidemiology and burden of chronic insomnia disorder in Europe: an analysis of the 2020 National Health and Wellness Survey

    by François-Xavier Chalet, Emiliano Albanese, Carlos Egea Santaolalla, Jason G. Ellis, Luigi Ferini-Strambi, Anna Heidbreder, Damien Léger, Kushal Modi, Charles M. Morin, Abisola Olopoenia

    Chronic insomnia disorder (CID) is considered a significant worldwide public health concern; however, its exact burden is unknown. We estimate its prevalence across France, Germany, Italy, Spain, and the United Kingdom, and assess the economic and humanistic burden for a broader insomnia population. This retrospective, cross-sectional, observational study used 2020 National Health and Wellness Survey (NHWS) data. Patients reporting insomnia were characterized to define CID. Health-related quality of life (HRQoL), work productivity, and healthcare resource use (HCRU) outcomes were assessed in four cohorts according to insomnia diagnosis and treatment status and examined using multivariable analyses according to Insomnia Severity Index categories. Among 62,319 respondents, 9,035 (21.2%) reported experiencing insomnia over the previous 12 months. CID prevalence rates were 5.5% to 6.7% across the five countries and 6.0% overall. HRQoL outcomes were persistently poorer in cohorts of patients diagnosed with insomnia than those with undiagnosed insomnia. Undiagnosed and treated insomnia patients reported the highest work presenteeism and total work productivity impairment and the highest number of emergency room and hospitalization visits than patients with insomnia (either treated or untreated). After adjusting for covariates, patients with severe insomnia reported significantly worse EQ-5D-5L utility scores, higher absenteeism and presenteeism rates, and more healthcare provider visits over the past 6 months than patients without insomnia (all p < 0.01). Our prevalence rates for CID align with published literature. A diagnosis of insomnia, use of sleep medications, and severity of insomnia are associated with poor quality of life, loss of work productivity, and higher HCRU, confirming the high unmet need and substantial humanistic and economic burden of CID.